Both share similar gastrointestinal side effects (nausea, diarrhea, vomiting, abdominal pain), but Trulicity has higher hypoglycemia risk when used with other diabetes medications
It activates three receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon
Similar to tirzepatide, semaglutide mimics the hormone GLP-1 and triggers the body to make more insulin when blood sugar levels rise after eating
Physical activity amplifies retatrutide results by preserving muscle mass during weight loss (critical for maintaining metabolic rate), increasing the caloric deficit beyond what appetite suppression alone achieves, and improving insulin sensitivity, which supports the metabolic effects of the medication
Two major blood vessels run directly beneath this tissue, the sublingual vein and the sublingual artery
It is important to understand that retatrutide is not currently approved for use in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
